Pregled bibliografske jedinice broj: 416463
Pregnancy outcome after gestational exposure to the new macrolides : a prospective multi-center observational study
Pregnancy outcome after gestational exposure to the new macrolides : a prospective multi-center observational study // European Journal of Obstetrics & Gynecology and Reproductive Biology, 141 (2008), 1; 31-34 doi:10.1016/j.ejogrb.2008.07.008 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 416463 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Pregnancy outcome after gestational exposure to the new macrolides : a prospective multi-center observational study
Autori
Bar-Oz, B. ; Diav-Citrin, O. ; Shechtman, S. ; Tellem, R. ; Arnon, J. ; Francetić, Igor ; Berkovitch, M. ; Ornoy, A.
Izvornik
European Journal of Obstetrics & Gynecology and Reproductive Biology (0301-2115) 141
(2008), 1;
31-34
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
pregnancy; macrolides; exposure; azithromyci; clarithromyci; roxithromycin; congenital malformations
Sažetak
To determine whether the use of the new macrolides (azithromycin, clarithromycin, roxithromycin) during the first trimester of pregnancy is associated with an increased risk of major malformations. In a prospective multi-center study, pregnancy outcome was compared between pregnant women exposed to one of the new macrolides during the first trimester of pregnancy and two comparison groups one exposed to other antibiotics and the other to other non-teratogenic medications. All women enrolled in the study called one of the three participating teratogen information services (TIS). Group 1 macrolides (n=161), group 2 other antibiotics (n=213) and group 3 non-teratogens (n=740). A total of 161 women exposed to the new macrolides (118 were exposed in the first trimester of pregnancy) and 953 from a comparison groups were followed up. The rate of major malformations in the study group was 4.1% compared to 2.1% in the other antibiotics exposed group (OR=1.41, 95% CI 0.47-4.23) and 3.0% in the non-teratogens exposed group. The rate of elective terminations of pregnancy was significantly higher in the exposed group in compare to both comparison groups. Our study, although relatively small sized, suggests that the use of the new macrolides during the first trimester of pregnancy does not represent an increased risk for congenital malformations strong enough for an induced abortion after such an exposure. Elective terminations of pregnancy because of early exposure to these medications should be reconsidered.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Projekti:
108-1080114-0016 - Modifikacija antimikrobne terapije i rezistencija patogenih mikroorganizama (Francetić, Igor, MZOS ) ( CroRIS)
Ustanove:
Medicinski fakultet, Zagreb
Profili:
Igor Francetić
(autor)
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
Uključenost u ostale bibliografske baze podataka::
- EMBASE (Excerpta Medica)